81920 Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices 

1HPs may include, but are not limited to, 

pediatricians, family physicians, adult primary care 

clinicians, obstetrician-gynecologists, physician 

assistants, advanced practice nurses/nurse 

practitioners, licensed practical nurses, registered 

nurses, nurse midwives, counselors, behavioral 

health clinicians, social workers, care coordinators, 

medical assistants, and patient care navigators. 

Dated: October 3, 2024. 

Alison Barkoff, 

Principal Deputy Administrator for the 

Administration for Community Living, 

performing the delegable duties of the 

Administrator and the Assistant Secretary for 

Aging. 

[FR Doc. 2024–23377 Filed 10–8–24; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission to OMB for 

Review and Approval; Public Comment 

Request; Evaluation of the Maternal 

and Child Health Bureau Pediatric 

Mental Health Care Access Program 

and the Screening and Treatment for 

Maternal Mental Health and Substance 

Use Disorders Program 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, 

HRSA submitted an Information 

Collection Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and approval. Comments 

submitted during the first public review 

of this ICR will be provided to OMB. 

OMB will accept further comments from 

the public during the review and 

approval period. OMB may act on 

HRSA’s ICR only after the 30-day 

comment period for this notice has 

closed. 

DATES: Comments on this ICR should be 

received no later than November 8, 

2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request a copy of the clearance requests 

submitted to OMB for review, email 

Joella Roland, the HRSA Information 

Collection Clearance Officer, at 

paperwork@hrsa.gov or call (301) 443– 

3983. 

SUPPLEMENTARY INFORMATION: 

Information Collection Request Title: 

Evaluation of the Maternal and Child 

Health Bureau Pediatric Mental Health 

Care Access Program and the Screening 

and Treatment for Maternal Mental 

Health and Substance Use Disorders 

Program, OMB No. 0906–xxxx—New. 

Abstract: This notice describes 

information collection requests for two 

of HRSA’s Maternal and Child Health 

Bureau programs: the Pediatric Mental 

Health Care Access (PMHCA) program 

and the Screening and Treatment for 

Maternal Mental Health and Substance 

Use Disorders (MMHSUD) program. The 

PMHCA program aims to promote 

behavioral health integration into 

pediatric primary care by developing 

and supporting state, regional, and tribal 

pediatric mental health care 

teleconsultation access programs. The 

MMHSUD program aims to support 

maternity care providers and clinical 

practices by supporting the 

development, improvement, and/or 

maintenance of statewide or regional 

behavioral health networks. Both 

programs support health professionals 

(HPs) 1 in their delivery of high-quality 

and timely screening, assessment, 

treatment, and referrals for their targeted 

populations (e.g., children, adolescents, 

and young adults for PMHCA programs; 

pregnant and postpartum people for 

MMHSUD programs) through the 

provision of clinical behavioral health 

teleconsultation, care coordination 

support/navigation (i.e., resource 

identification and referrals), and 

training and education. Additionally, 

the PMHCA and MMHSUD programs 

focus on reducing racial, ethnic, and 

geographic disparities in access to care, 

especially in rural and other 

underserved areas. 

The information will be collected 

from PMHCA and MMHSUD award 

recipient programs funded in 2021, 

2022, or 2023 and from participants in 

and stakeholders of those programs: 

• The 2021 and 2022 PMHCA 

programs are authorized by 42 U.S.C. 

254c–19 (sec. 330M of the Public Health 

Service Act), using funding provided by 

Section 2712 of the American Rescue 

Plan Act of 2021 (Pub. L. 117–2). 

• The 2023 PMHCA programs are 

authorized by 42 U.S.C. 254c–19 (sec. 

330M of the Public Health Service Act), 

as amended by Section 11005 of the 

Bipartisan Safer Communities Act (Pub. 

L. 117–159). 

• The 2023 MMHSUD programs are 

authorized by 42 U.S.C. 247b–13a (sec. 

317L–1 of the Public Health Service 

Act). 

To evaluate progress made toward the 

programs’ goals, this data collection will 

use the following eight instruments: (1) 

HP Survey, (2) Practice-Level Survey, 

(3) Program Implementation Survey, (4) 

Behavioral Health Consultation Provider 

Semi-Structured Interview (SSI), (5) 

Care Coordinator SSI, (6) Champion SSI, 

(7) Community-Based and Other 

Resources SSI, and (8) Program 

Implementation SSI. 

A 60-day notice was published in the 

Federal Register on May 28, 2024, 89 

FR 46143–44. HRSA received two 

public comments, which included 13 

recommendations. All 

recommendations were considered, as 

detailed below, and no changes were 

made to the current information 

collection described in this notice as a 

result of the recommendations. 

Two recommendations focused on 

defining terms. One recommended use 

of the term ‘‘mental and behavioral 

health’’ in place of ‘‘behavioral health’’ 

and ‘‘infant, child, and adolescent’’ in 

place of ‘‘child and adolescent’’ in any 

survey language. HRSA selected 

‘‘behavioral health’’ as the most concise 

and accepted term after consideration of 

definitions from national associations, 

federal agencies, and experts in the 

field. HRSA noted that the ‘‘child and 

adolescent’’ terminology is not used in 

the surveys for the HRSA evaluation of 

the PMHCA and MMHSUD programs. 

Another recommended that HRSA 

define PMHCA program training 

activities. In the Notices of Funding 

Opportunity that awardees responded 

to, HRSA describes various modalities/ 

formats for training (e.g., Project 

Extension for Community Health Care 

Outcomes, Resource for Advancing 

Children’s Health, learning 

collaboratives, in person, synchronous, 

asynchronous) as well as potential 

topics for training (e.g., psychiatric 

disorders and medications, screening 

and treatment protocols, practice 

transformation processes, traumainformed care). Reflective of trainingrelated program requirements, HRSA 

will collect data on the number of 

trainings attended by HPs, modality for 

training received, the number of 

providers trained, the number of 

trainings by topic, training methods, 

and materials used. Training is defined 

in the surveys using the survey question 

response options (e.g., in-person 

training event, webinar, self-study with 

program resources, video conferencing, 

learning collaborative [Project Extension 

for Community Health Care Outcomes, 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices 81921 

Resource for Advancing Children’s 

Health], and others). 

Three recommendations discussed 

data: the need for data to be comparable 

across PMHCA programs while still 

considering differences across these 

programs; ensuring data collection is 

conducted in a manner that is clear and 

relevant for the full range of anticipated 

data collection participants (e.g., HPs, 

program champions, community 

resource representatives); and the value 

of data to inform understanding of 

differences in rural, urban, and 

suburban access to behavioral health 

care. No changes will be made to the 

information collection forms in 

response to these recommendations 

because the data collection instruments 

are already responsive to these points. 

First, HRSA will record and analyze 

program differences such as program 

structure, funding, history, and size to 

help inform data findings across 

program types. Second, HRSA will 

collect data about settings in which 

patients live, and about practice setting, 

with response options including urban, 

suburban, rural, and frontier. Surveys 

also collect the ZIP Code of the primary 

clinical practice. While specific data on 

travel for mental and behavioral health 

care will not be collected, the Care 

Coordinator SSIs will provide 

qualitative insights on barriers to 

referrals, geographic areas of referrals, 

and strategies to mitigate barriers, which 

may include addressing travel time. 

One recommendation expressed 

concerns about HRSA’s plan to assess 

changes over time in health 

practitioners’ capacity to address 

patients’ mental and behavioral health 

and access to mental and behavioral 

health care through screening indicating 

that PMHCA programs are typically 

most valuable after the need for mental 

or behavioral health interventions has 

been identified rather than in 

conducting initial screenings. For this 

data collection, HRSA has 

operationalized capacity broadly as 

behavioral health knowledge, skills, 

practice, and attitudes. Evaluation 

questions focus on change in knowledge 

and skills; screening, assessment, 

treatment, and referral; attitudes about 

providing behavioral health care; and 

how change over time differed based on 

frequency and modality of program 

access, treatment location, 

demographics, and treatment settings. 

These questions allow HRSA to measure 

changes in these different aspects of 

provider capacity and describe how 

these changes differ across the contexts 

listed above (e.g., treatment location, 

treatment settings). 

Four recommendations supported 

collecting patient-level data and the use 

of accessible automated collection 

techniques and minimally invasive 

software and strategies. HRSA disclosed 

that patient level data will not be 

collected under this information 

collection. All technology used for the 

survey administration will meet federal 

requirements for Section 508 

accessibility. Survey data collection for 

the evaluation will be primarily through 

web-linked survey administered via 

email and via survey platform. 

Qualitative data collection and SSIs will 

be conducted virtually (e.g., Microsoft 

Teams, Zoom). 

One recommendation supported the 

proposed mixed evaluation plan and 

approach. HRSA will implement 

outcome and process evaluations, using 

a mixed-methods design, with primary 

and secondary quantitative and 

qualitative data collection activities 

across all awardees. 

One recommendation expressed 

support of the estimated burden and 

asked how grantees will proceed if they 

do not employ a likely respondent. 

HRSA will not require participation in 

that data collection activity if an 

awardee does not employ a likely 

respondent. 

One recommendation suggested that 

HRSA brand HRSA–MMHSUD 

programming in marketing leading up to 

the evaluation so that providers can 

more easily respond to questions. HRSA 

has developed a promotion packet of 

materials with branding guidance and 

customizable messages for awardees to 

use to (1) increase HP and practice 

engagement with their programs and (2) 

encourage participation in evaluation 

surveys. Additionally, the surveys will 

be customized for each program with 

the program name and logo, as 

applicable. 

Need and Proposed Use of the 

Information: HRSA needs this 

information to evaluate the PMHCA and 

MMHSUD programs to guide future 

decisions regarding increasing HPs’ 

capacity to address patients’ behavioral 

health and access to behavioral health 

services. Specifically, data collected for 

the evaluation will be used to study the 

efforts of the PMHCA and MMHSUD 

programs to achieve key outcomes (e.g., 

increase in access to behavioral health 

services; HPs trained; identification of 

community-based resources, including 

counselors or family service providers) 

and to measure whether and to what 

extent awardee programs are associated 

with changes in these outcomes. The 

evaluation will examine changes over 

time across PMHCA and MMHSUD 

programs, regarding the PMHCA- and 

MMHSUD-enrolled/participating HPs’ 

and practices’ (1) capacity to address 

patients’ behavioral health and access to 

behavioral health care, through 

screening, assessment, treatment, and 

referral for behavioral health conditions; 

and (2) use of program services (e.g., 

consultation, care coordination, 

training). 

Likely Respondents: 

• HP Survey: Pediatricians, family 

physicians, obstetrician-gynecologists, 

physician assistants, advanced practice 

nurses/nurse practitioners, licensed 

practical nurses, registered nurses, 

counselors, social workers, medical 

assistants, and patient care navigators 

• Practice-Level Survey: Practice 

managers (e.g., office managers, office 

leadership, nurse champions) 

• Program Implementation Survey: 

Cooperative agreement-funded project 

directors/principal investigators 

• Behavioral Health Consultation 

Provider SSI: PMHCA and MMHSUD 

program-level behavioral health 

consultation providers 

• Care Coordinator SSI: PMHCA and 

MMHSUD program-level care 

coordinators 

• Champion SSI: PMHCA and 

MMHSUD program champions (e.g., 

HPs, community, and social service 

specialists) 

• Community-Based and Other 

Resources SSI: PMHCA and MMHSUD 

program-level community resource 

partner representatives (e.g., counselors, 

social workers, other community and 

social service specialists, other HPs/ 

support workers, practice/organization 

managers) 

• Program Implementation SSI: 

Cooperative agreement-funded project 

directors/principal investigators 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating, and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

The burden estimates below have 

changed from the estimates of burden 

provided in the previous notice (60-day 

notice published on May 28, 2024, 89 


khammond on DSKJM1Z7X2PROD with NOTICES
81922 Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices 

FR 46143–44). The estimated burden 

total is slightly higher in this revised 

notice because it incorporates estimates 

for an MMHSUD program that was 

funded following submission of the 

previous notice. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

HP Survey ............................................................................ 23,256 1 23,256 0.33 7,674.48 

Practice-Level Survey .......................................................... 6,172 1 6,172 0.33 2,036.76 

Program Implementation Survey ......................................... 67 1 67 0.33 22.11 

Behavioral Health Consultation Provider SSI ...................... 67 1 67 0.75 50.25 

Care Coordinator SSI .......................................................... 67 1 67 0.75 50.25 

Champion SSI ...................................................................... 67 1 67 0.50 33.50 

Community-Based and Other Resources SSI ..................... 50 1 50 0.50 25.00 

Program Implementation SSI ............................................... 134 1 134 1.00 134.00 

Total .............................................................................. 29,880 ........................ 29,880 ........................ 10,026.35 

Amy P. McNulty, 

Deputy Director, Executive Secretariat. 

[FR Doc. 2024–23293 Filed 10–8–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

SCORCH (Single Cell Opioid Responses in 

the Context of HIV) Program: Data 

Coordination, Analysis, and Scientific 

Outreach; Data Mining and Functional 

Validation. 

Date: November 15, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Caitlin Elizabeth Angela 

Moyer, Ph.D., Scientific Review Officer, 

Scientific Review Branch, National Institute 

on Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 443–4577, caitlin.moyer@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Ending 

the Epidemic: New Models of Integrated HIV/ 

AIDS, Addiction, and Primary Care Services. 

Date: November 15, 2024. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–5843, trinh.tran@

nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIH 

Support for Conferences and Scientific 

Meetings. 

Date: November 19, 2024. 

Time: 1:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Li Rebekah Feng, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–7245, rebekah.feng@

nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA). 

Date: November 21, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse, Special Emphasis Panel; NIDA 

Avant-Garde Program for HIV and Substance 

Use Disorder Research; NIDA Avenir Award 

Program for HIV and Substance Use Disorder 

Research. 

Date: December 9, 2024. 

Time: 9:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Avant-Garde Program for HIV and Substance 

Use Disorder Research; NIDA Avenir Award 

Program for HIV and Substance Use Disorder 

Research. 

Date: December 12, 2024. 

Time: 9:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 


khammond on DSKJM1Z7X2PROD with NOTICES